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Assessment of the course 
of acute pancreatitis in the light 
of aetiology: a systematic review 
and meta‑analysis
Emese Réka Bálint1, Gabriella Fűr1, Lóránd Kiss1, Dávid István Németh2, Alexandra Soós2,4, 
Péter Hegyi2,3, Zsolt Szakács2, Benedek Tinusz2, Péter Varjú5, Áron Vincze5, Bálint Erőss2, 
József Czimmer2, Zoltán Szepes6, Gábor Varga7 & Zoltán Rakonczay Jr.1*
The main causes of acute pancreatitis (AP) are biliary disease, alcohol consumption, 
hypertriglyceridaemia (HTG) and endoscopic retrograde cholangiopancreatography (ERCP). The aim 
of this meta‑analysis was to evaluate the effects of these aetiological factors on the severity and 
outcome of AP. Pubmed and Embase were searched between 01/01/2012 and 31/05/2020. Included 
articles involved adult alcoholic, biliary, HTG‑ or post‑ERCP AP (PAP) patients. Primary outcome was 
severity, secondary outcomes were organ failures, intensive care unit admission, recurrence rate, 
pancreatic necrosis, mortality, length of hospital stay, pseudocyst, fluid collection and systematic 
inflammatory response syndrome. Data were analysed from 127 eligible studies. The risk for non‑mild 
(moderately severe and severe) condition was the highest in HTG‑induced AP (HTG‑AP) followed by 
alcoholic AP (AAP), biliary AP (BAP) and PAP. Recurrence rate was significantly lower among BAP vs. 
HTG‑AP or AAP patients (OR = 2.69 and 2.98, 95% CI 1.55–4.65 and 2.22–4.01, respectively). Mortality 
rate was significantly greater in HTG‑AP vs. AAP or BAP (OR = 1.72 and 1.50, 95% CI 1.04–2.84 and 
0.96–2.35, respectively), pancreatic necrosis occurred more frequently in AAP than BAP patients 
(OR = 1.58, 95% CI 1.08–2.30). Overall, there is a potential association between aetiology and the 
development and course of AP. HTG‑AP is associated with the highest number of complications. 
Furthermore, AAP is likely to be more severe than BAP or PAP. Greater emphasis should be placed on 
determining aetiology on admission.
Abbreviations
AP  Acute pancreatitis
AAP  Alcohol-induced/alcoholic acute pancreatitis
BAP  Biliary acute pancreatitis
CI  95% Confidence interval
ERCP  Endoscopic retrograde cholangiopancreatography
HTG-AP  Hypertriglyceridaemia-induced acute pancreatitis
HTG  Hypertriglyceridaemia
ICU  Intensive care unit
LOS  Length of hospital stay
MOF  Multiple organ failure
OF  Organ failure
OR  Odds ratio
PAP  Post-endoscopic retrograde cholangiopancreatography-induced acute pancreatitis
POF  Persistent organ failure
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PUF  Pulmonary failure
RAC  Revised Atlanta Classification
SIRS  Systematic inflammatory response syndrome
TOF  Transient organ failure
Acute pancreatitis (AP) is a sudden inflammatory disease of the pancreas. In the last 20 years, the incidence of the 
disease has increased by more than 20%1,2. Nowadays, AP is one of the most common reasons for hospitalization 
in case of gastrointestinal  diseases3.
Gallstones represent the main aetiological background of AP globally (42%), which are diagnosed by imag-
ing techniques and liver function  tests4. Gallstone-related or biliary AP (BAP) occurs twice as often as alcohol-
induced AP (AAP)4. AAP is caused by regular, excessive alcohol consumption usually with a clinical history 
of > 5 years and > 50–100 g/day5. Hypertriglyceridaemia (HTG) with serum triglyceride concentrations > 11.3 mM 
is the third most common (9%) known aetiological factor of the  disease6–8. Less frequent causes of AP include 
endoscopic retrograde cholangiopancreatography (ERCP), hypercalcaemia, pancreas divisum, tumours, genetic 
polymorphisms and  drugs9. To date, no standardized diagnostic criteria exist for post-ERCP AP (PAP). The 
guidelines recommended by Cotton et al.10 are most commonly applied, which suggest PAP to be diagnosed if 
pancreatitis develops within 24 h after the procedure.
Based on the Revised Atlanta Classification (RAC), AP severity can be categorized into three groups: mild, 
moderately severe and  severe11. Although the majority of cases are mild with a self-limiting  course11, the mor-
tality rate of severe AP can reach 30% which underlies the desperate need of finding proper  treatment12. Organ 
failure (OF) is the most important determinant of this classification  system11. Patients with mild AP have no 
organ dysfunction and usually recover within a week. Moderately severe AP resolves slower and might require 
interventions because of the presence of transient organ failure (TOF, < 48 h). Severe AP results in persistent 
organ failure (POF) which lasts > 48 h. Multiple organ failure (MOF) is defined as failure of two or more organ 
systems, which can be transient or  persistent13. The three extrapancreatic organs most commonly affected by AP 
are the lungs, the heart and the  kidneys11. Approximately 25% of AP patients develop severe complications and 
have to be admitted to an intensive care unit (ICU)14. Local complications can also occur in cases of moderately 
severe and severe AP, which include acute peripancreatic fluid collections, pancreatic pseudocysts, acute necrotic 
collections and walled-off  necrosis11. About 20% of patients experience recurrent AP (RAP), which refers to a 
clinical condition defined by repeated episodes of  AP15. 10% of AP patients with a single episode and 36% with 
RAP progress to chronic pancreatitis (CP)15. The risk of progression to CP increases with excessive alcohol 
consumption, smoking and male gender. 5% of CP patients develop pancreatic  cancer16.
Although there are several risk factors, it is difficult to predict which patient will develop mild, moderately 
severe or severe AP. To date, numerous clinical studies have investigated the effect of aetiology on AP progression. 
However, to the best of our knowledge, there have been no efforts to summarize clinical data on how various 
aetiological backgrounds affect the severity and course of AP. Consequently, this study was undertaken to reveal 
the impact of the above-mentioned aetiologies (HTG-AP, AAP, BAP, PAP) by performing thorough literature 
search and meta-analysis on available clinical data.
Methods
This systematic review and meta-analysis followed the recommendations of Stroup et al.17 and was conducted 
in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses  guidelines18 (Supplemen-
tary Table S1). The analysis was based on the Problem, Intervention, Comparison intervention and Outcome 
(PICO)  model18 as follows: AP patients with alcoholic, biliary, hypertriglyceridaemic and post-ERCP aetiologies 
were compared in order to examine the effect of aetiology on disease outcomes. Primary outcome was sever-
ity, secondary outcomes were POF, MOF, TOF, ICU admission, recurrence rate, mortality, pancreatic necrosis, 
pulmonary failure (PUF), renal failure, length of hospital stay (LOS), pseudocyst, fluid collection, and systematic 
inflammatory response syndrome (SIRS).
The protocol for the meta-analysis was registered in the PROSPERO database on 15/05/2018 (https ://www.
crd.york.ac.uk/PROSP ERO/, ID: CRD42018093574).
Search strategy. Literature search was conducted in the electronic databases Embase and Pubmed from 
publication date 01/01/2012 to 31/05/2020. The reason for the start date is that the RAC was introduced in 
2012, which provides the most accepted and widespread criteria for determining AP severity. The following 
search query was used for Embase: (alcohol* OR ethanol* OR biliary OR gallstone OR cholelithiasis OR ’post-
ercp’ OR ’post ercp’ OR idiopathic OR triglyceride OR hypertriglyceridemia OR hyperlipidemia OR severity OR 
severe OR mild OR moderate) AND acute AND pancreatitis NOT (’conference abstract’/it OR ’review’/it)) AND 
(2012:py OR 2013:py OR 2014:py OR 2015:py OR 2016:py OR 2017:py OR 2018:py OR 2019:py OR 2020:py). In 
Pubmed, the following search terms were applied: (alcohol* OR ethanol* OR biliary OR gallstone OR cholelithi-
asis OR "post-ercp" OR "post ercp" OR idiopathic OR triglyceride OR hypertriglyceridemia OR hyperlipidemia 
OR severity OR severe OR mild OR moderate) AND acute AND pancreatitis NOT Review[ptyp] NOT Case 
Reports[ptyp]. The search was restricted to studies written in English or in Hungarian.
Eligibility criteria. All randomised trials, retrospective and prospective cohort studies were included that 
involved adult patients with AP and relevant data (primary and secondary outcomes) are categorized according 
to the aetiology of the disease. Four major disease backgrounds were included: alcohol abuse, HTG, biliary dis-
ease and post-ERCP. Articles that studied only one aetiological group or compared one aetiological group with 
another group called others or non-… (e.g. alcohol vs. non-alcohol) were excluded. Non-human studies or arti-
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cles with data from patients younger than 18 years of age were not included. In case of cohort overlap between 
studies, only the most recent study was included unless a prior study had higher quality.
When assessing AP severity, only studies were included where severity was defined according to the RAC, 
because in this case it was crucial to present a consistent and clear definition for the analysis. Articles were 
also excluded if only one or two of the three severity groups were analysed. Both local complications and OFs 
could lead to serious conditions and death which are characteristic features of moderately severe and severe AP. 
Therefore, these two groups were combined in our study, and are referred to as “non-mild” disease forms and 
compared to the mild group. In cases of outcomes other than severity, using only the RAC was not in the criteria.
Study selection and data extraction. Titles and abstracts of publications were screened independently 
by two review authors (E.R.B. and G.F.) to identify studies that potentially meet inclusion criteria. The full texts 
of these potentially eligible studies were independently assessed for eligibility by the same two review authors. 
Disagreement between reviewers was resolved by discussion with other two colleagues (L.K. and Z.R.). E.R.B. 
and G.F. independently extracted study characteristics (author, title, journal, study location, inclusion period, 
number of centres involved, type of study, number of participants) and outcome data (severity, POF, MOF, TOF, 
ICU admission, recurrence rate, mortality, pancreatic necrosis, PUF, renal failure, LOS, pseudocyst, fluid collec-
tion, SIRS), which were recorded on a standardized Microsoft Excel spreadsheet. Discrepancies were resolved 
by discussion.
Quality assessment. Methodological quality of the articles was assessed by applying the Quality In Prog-
nosis Studies (QUIPS)  tool19 (Supplementary Table S2). This considers the following domains: study participa-
tion, study attrition, prognostic factor measurement, outcome measurement, study confounding, and statistical 
analysis and reporting. All domains were scored by three individual researchers (E.R.B., G.F., L.K., each article 
was assessed by at least two of them). The overall risk of bias was considered:
• low if < 3 domains were rated a moderate risk of bias and all others were rated a low risk of bias,
• moderate if ≥ 3 domains were rated a moderate risk of bias and all others were rated a low risk of bias,
• high if ≥ 1 domain was rated a high risk of bias, irrespective of all other domains.
Consensus was reached after classification by the individual researchers.
Data analyses. Statistical analysis was performed with Stata 11 SE (StataCorp LLC, College Station, TX, 
USA). The investigated aetiologies were analysed pairwise. Odds ratios (ORs) calculated from patient numbers 
were used to compare outcomes in different aetiologic groups. ORs were pooled using the random effects model 
with the DerSimonien–Laird estimation and displayed on forest plots. Summary OR estimation, p value and 
95% confidence interval (CI) were calculated. P < 0.05 was considered as significant difference from summary 
OR = 1. BAP was defined as primary reference group, the other aetiologies were ranked in the following order: 
AAP, HTG-AP, PAP.
Statistical heterogeneity was analysed using the  I2 statistic and the chi-square test to acquire probability val-
ues; p < 0.1 was defined to indicate significant heterogeneity. The small-study effect (in case of comparisons with 
at least 10 articles) was visually investigated on funnel plots and was also confirmed by Egger’s test. Sensitivity 
analysis was performed to examine the robustness of our results.
Results
Study selection. The search strategy identified 11,288 records. After removing duplicates 7733 articles were 
retrieved. Out of these, 456 records seemed to be relevant to the study question based on screening by title or 
abstract. After assessing the articles in full text, 328 records had to be excluded with different reasons (see details 
in Fig. 1). Finally, 127 publications fulfilled the eligibility criteria.
Characteristics of studies included. The majority of the included cohort studies (108 out of 128) col-
lected data from the 2010′s. Our meta-analysis contains 102  single20–121 and 23 multicentre  studies122–144. In two 
cases, there were no relevant data regarding the number of centres  involved145,146. Sample sizes ranged from 11 
to 1,165,777. Only the data of the four types of AP (AAP, BAP, HTG-AP, PAP) were analysed. Detailed charac-
teristics of the included studies are provided in Supplementary Table S3. During quality assessment, we evalu-
ated patient selection, comparability of the groups, and outcome data, which are presented in Supplementary 
Table S4.
Risk of bias assessment. According to the QUIPS checklist, most of the included studies had an overall 
moderate risk of bias (80, 63%; Supplementary Figure S1). 30 studies (23.4%) had low and 17 (13.3%) had high 
risk of bias. High risk was mainly due to the confounding factors which showed significant difference between 
the analysed aetiological groups. Moderate risk of bias resulted mainly from „Study confounding” and „Statisti-
cal Analysis and Reporting”, furthermore „Prognostic factor measurement” was also missing in a relatively high 
number (66.9%) of included studies. A detailed analysis can be found in Supplementary Table S4.
Clinical outcomes. Severity. HTG proved to induce non-mild AP in a significantly higher number of 
cases than the other aetiological factors (Figs. 2, 3). ORs of non-mild cases in HTG-AP were 1.35 [CI 1.12–1.63] 
and 1.35 [CI 1.13–1.62] vs. AAP and BAP, respectively (Fig. 2a, b). PAP also appeared to be significantly less 
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severe compared to HTG-AP (Fig. 3a; OR: 0.38 [CI 0.15–0.98]) or AAP (Fig. 3b; OR: 0.43 [CI 0.25–0.74]), while 
no significant difference could be detected between the severities of BAP and PAP (Supplementary Figure S2]). 
Alcoholic aetiology significantly increased AP severity compared to biliary-related events (Fig. 4; OR: 1.36 [CI 
1.15–1.60]). We found heterogeneity in the comparison of HTG-AP vs. BAP, HTG-AP vs. PAP, AAP vs. BAP, 
PAP vs. AAP, BAP vs. PAP (Figs. 2b, 3, 4 and Supplementary Figure S2). No signs of small-study effect were 
detected in any comparison (Supplementary Figure S3).
Organ failures, intensive care unit admission, and systematic inflammatory response syndrome. No significant 
difference was found in POF between any aetiological groups (AAP vs. BAP, HTG-AP vs. AAP, HTG-AP vs. 
BAP; Fig. 5a; Supplementary Figure S4). No signs of small-study effect were found in POF in the comparison of 
AAP vs. BAP (Supplementary Figure S5a). There were no significant differences in the occurrences of MOF, TOF 
or renal failure between AAP and BAP (Fig. 5b and Supplementary Figures S6a,b, respectively). PUF occurred 
more frequently in HTG-AP patients compared to BAP (Supplementary Figure S7a; OR: 2.39 [CI 1.06–5.39]), 
while AAP and BAP patients did not differ in this respect (Supplementary Figure S7b). The frequency of ICU 
admission was similar in AAP and BAP patients (Supplementary Figure S8). More AAP patients developed SIRS 
than PAP patients (Supplementary Figure S9a, OR: 0.40 [CI 0.21–0.77]. The rate of SIRS did not differ when 
comparing other patient groups (Supplementary Figure S9b,c). Heterogeneity was found in the comparison of 
renal failure, PUF and ICU admission between AAP and BAP (Supplementary Figures S6b, S7b, S8).
Recurrence rate and length of hospital stay. Recurrence rate was significantly higher in AAP vs. BAP patients 
(Supplementary Figure S10a; OR: 2.98 [CI 2.22–4.01]) and in HTG-AP vs. BAP patients (Supplementary Fig-
ure S10b; OR: 2.69 [CI 1.55–4.65]). However, AP did not reoccur more frequently due to alcoholic aetiology than 
Figure 1.  PRISMA 2009 flow diagram for identification of relevant articles.
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Figure 2.  Forest plot showing the comparison of disease severity in (A) HTG-AP and AAP, p = 0.001; (B) 
HTG-AP and BAP, p = 0.001. Filled diamonds represent the ORs derived from the articles analysed. Horizontal 
bars represent CI. Empty diamond shows the overall OR (middle of the diamond and CIs are the edges) for non-
mild (moderately severe and severe groups based on the Revised Atlanta Classification) disease. Heterogeneity 
of the results was presented by I-square and p value.
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Figure 3.  Forest plot showing the comparison of disease severity in (A) HTG-AP and PAP, p = 0.045; (B) AAP 
and PAP, p = 0.002. Filled diamonds represent the ORs derived from the articles analysed. Horizontal bars 
represent CI. Empty diamond shows the overall OR (the middle of the diamond, CIs are the edges) for non-mild 
disease.
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HTG or post-ERCP (Supplementary Figure S11a,b). Recurrence rate was also similar in BAP and PAP patients 
(Supplementary Figure S11c). Patients of the analysed aetiologies were hospitalized for a similar length of time 
(Supplementary Figure S12a,b). We found heterogeneity in the comparison of all cases of LOS and all cases of 
recurrence rate, except for the comparison between AAP and HTG-AP (Supplementary Figure S11a). No signs 
of small-study effect could be detected in case of recurrence rate or LOS (Supplementary Figure S5b,c).
Mortality and pancreatic necrosis. Mortality rate proved to be significantly higher in HTG-AP than in AAP 
(Fig. 6; OR: 1.72 [CI 1.04–2.84]), but no statistical difference was found between any other patient groups (Sup-
Figure 4.  Forest plot showing the comparison of disease severity in AAP and BAP, p < 0.001. Filled diamonds 
represent the ORs derived from the articles analysed. Horizontal bars represent CI. Empty diamond shows the 
overall OR (middle of the diamond, CIs are the edges) for non-mild disease.
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Figure 5.  Forest plot showing the effect of different disease aetiologies on POF and MOF. The effects of BAP vs. 
AAP on (A) POF, p = 0.102; and (B) MOF, p = 0.284. Filled diamonds represent the ORs derived from the articles 
analysed. Horizontal bars represent CI. Empty diamond shows the overall OR (the middle of the diamond, CIs 
are the edges).
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plementary Figures S13 and S14). In the comparison of AAP and BAP a large proportion of patients came from 
one study contributing 1,165,777 subjects (accounting for 12.76% weight, Supplementary Figure S13a). How-
ever, sensitivity analysis showed that the results remained similar when this study was excluded (OR = 0.96 [CI 
0.75–1.23]; Supplementary Figure S15). Pancreatic necrosis was reported more often in AAP than BAP patients 
(Fig. 7a, OR = 1.58 [CI 1.08–2.30]). No significant difference was detected in any other comparisons regarding 
necrosis (Fig. 7b,c). Heterogeneity was found in the comparison of mortality rate between BAP and HTG-AP, 
AAP and BAP (Supplementary Figure S13), and in case of necrosis when AAP and BAP groups were compared 
(Fig. 7a). We found signs of the small-study effect in case of mortality in the comparison of AAP and BAP (Sup-
plementary Figure S16).
Pseudocyst, fluid collection. There was no significant difference in the presence of fluid collection or pseudo-
cysts in the available comparisons (Supplementary Figure S17). We found heterogeneity in case of fluid collec-
tion (AAP vs. BAP) and pseudocyst (HTG-AP vs BAP).
Discussion
This is the first detailed meta-analysis investigating the relationship between different aetiologies (alcohol abuse, 
biliary, HTG, post-ERCP) and the course of AP. Our study revealed that the prevalence of severe and moder-
ately severe (non-mild) disease forms was highest in case of HTG-AP which was followed by AAP, BAP and 
PAP (Table 1). Due to the large number of included articles and patients, our results have strong evidence in 
case of the severity outcome. These are also in accordance with our earlier  observations147 and the data of Wang 
et al.148. However, previously we compared the severe disease category to moderately severe and mild groups, 
which has less relevance than merging the severe and moderately severe groups as we did in the current study. 
Furthermore, our previous study and that of Wang et al.148 compared the characteristics and outcome of HTG-AP 
to non-HTG-AP patients, without classifying non-HTG-AP group any further according to aetiology. Impor-
tantly, non-HTG-AP group is rather heterogenous and it cannot be decided whether all aetiological subgroups 
included in non-HTG-AP are less severe than HTG-AP or some of the subgroups are basically more severe 
than HTG-AP but due to other much milder subtypes, HTG-AP turns out to be the most severe disease form. 
In addition, non-HTG-AP included all aetiologies (“idiopathic” and “other” as well) except HTG-AP, while we 
only analysed well-defined and clear aetiologies. Therefore, the current meta-analysis provides a more refined 
Figure 6.  Forest plot showing the effect of HTG-AP and AAP on mortality, p = 0.034. Filled diamonds 
represent the ORs derived from the articles analysed. Horizontal bars represent CI. Empty diamond shows the 
overall OR (the middle of the diamond, CIs are the edges).
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Figure 7.  Forest plot showing the effects of different disease aetiologies on pancreatic necrosis. The effects of 
(A) BAP vs. AAP, p = 0.019; (B) AAP vs. PAP, p = 0.982; (C) BAP vs. PAP, p = 0.674. Filled diamonds represent 
the ORs derived from the articles analysed. Horizontal bars represent CI. Empty diamond shows the overall OR 
(the middle of the diamond, CIs are the edges).
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picture of the outcomes. Wang et al.148 evaluated AP severity using the APACHE-II scoring system, but this does 
not specifically define AP severity.
In our study, no difference could be observed between any aetiological groups in POF (Table 1). Although 
HTG-AP and AAP exhibited the most severe forms of AP from an aetiologic point of view, the data of POF does 
not support it. This can be explained by the fact that POF associated with AP was assessed in HTG-AP patients 
only in three of the articles included in our meta-analysis38,77,90. In the study of Wang et al.148 POF was most 
commonly observed in HTG-AP, which is in accordance with our results for severity. Although several articles 
evaluate characteristic features of severe AP such as POF, they focus exclusively on severe AP patients. For this 
reason, these could not be utilized in our analysis.
MOF is another distinctive feature of severe and moderately severe AP. In the current study, no significant 
difference could be detected in MOF between any of the analysed groups. Similarly, in a previous study, we did 
not find differences in MOF among HTG-AP vs. non-HTG-AP  patients147. Tai et al.149 also found a higher risk 
for the severe form of AP in HTG-AP patients compared to BAP. They diagnosed MOF more frequently in BAP 
patients, however, there was no difference in single OFs (renal, heart, pulmonary).
AP patients with systemic complications eventually end up in ICU. In case of this outcome, only one com-
parison could be performed: no significant difference was found between AAP and BAP (Table 1), which is 
supported by our previous  findings147.
The 27% recurrence rate of AP in the  1990s150 has nowadays decreased to about 20%151, which could be 
explained by better diagnosis and treatment after the first attack. In our study, alcoholic and hypertriglyceri-
daemic aetiologies caused more AP recurrence than biliary, while the repeated hospitalization for AAP and 
HTG-AP patients was similar. Tai et al. also found higher recurrence rate of HTG-AP than  BAP149. Other stud-
ies drew the conclusion that alcohol is the most frequent aetiological factor for recurrent  AP150,151. Suchsland 
et al.151 analysed the risk factors for readmittance in AP, most of which were related to alcohol abuse, so these 
patients have a higher risk for disease recurrence after discharge. In case of BAP, delayed cholecystectomy could 
be responsible for  recurrence152,153.
Our study has shown that HTG-AP led to significantly higher mortality rate than AAP. However, no signifi-
cant difference could be detected between the other aetiological groups. BAP used to have a higher mortality than 
AAP; however, this rate has decreased in the last decade due to improved supportive  care154. Several studies have 
reported that mortality rate was not influenced by aetiological  factors155,156. Other studies stated that HTG-AP 
did not cause significantly higher mortality rate, even though it led to higher severity and complication rates 
compared to other aetiological  factors157,158. Wang et al.148 concluded that HTG-AP caused higher mortality rate 
than non-HTG-AP, while Kiss et al.147 did not find significant difference in this respect. Based on the current 
study, there is no strong relationship between aetiology of AP and mortality.
HTG carried the greatest risk for non-mild (moderately severe and severe) AP, which was followed by AAP; 
the least severe disease forms were observed in BAP and PAP. One of the possible pathomechanisms is that 
lipotoxicity mediated by unsaturated fatty acids contributes to necrosis, OF (eg. cardiovascular diseases) and 
 mortality159. Experimental studies also demonstrated that HTG exacerbates the severity of  AP159,160. Fatty acid 
Table 1.  Summary of the results of our study. AAP alcohol-induced acute pancreatitis, BAP biliary acute 
pancreatitis, HTG-AP hypertriglyceridaemia-induced acute pancreatitis, ICU intensive care unit, LOS length 
of hospital stay, MOF multiple organ failure, PAP post endoscopic retrograde cholangiopancreatography-
induced acute pancreatitis, POF persistent organ failure, PUF pulmonary failure, SIRS systematic inflammatory 
response syndrome, TOF transient organ failure. Statistically siginificant difference (p < 0.05) was presented 
with < ; ≸ shows no significant difference.
Severity HTG-AP > AAP > BAP ≸ PAP
POF AAP ≸ BAPHTG-AP ≸ [AAP/BAP]
MOF AAP ≸BAP
TOF AAP ≸BAP
PUF HTG-AP > BAP ≸ AAP
Renal failure AAP ≸BAP
ICU admission AAP ≸ BAP
SIRS BAP ≸ AAP > PAPBAP ≸ PAP
Recurrence rate
[HTG-AP/AAP] > BAP
HTG-AP ≸ AAP
PAP ≸ [AAP/ BAP] 
Mortality
HTG-AP > AAP
[HTG-AP/AAP/PAP] ≸ BAP
AAP ≸ PAP
Necrosis AAP > BAPPAP ≸ [AAP/BAP]
Pseudocyst HTG-AP ≸ BAPAAP ≸ BAP
LOS [HTG-AP/AAP] ≸ BAP
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administration resulted in elevated intracellular  Ca2+ levels in pancreatic acinar cells and impaired mitochon-
drial  function161,162. HTG-AP is often accompanied by one or more secondary factors (alcoholism, medications, 
uncontrolled diabetes mellitus, physical inactivity), which can further aggravate the severity of the  disease163–166. 
Furthermore, elevated serum chylomicron concentration during HTG increases viscosity, causing reduced blood 
flow in microvessels and resulting in ischemic conditions. This could be an additional risk factor for a severe 
form of  AP161,162.
Determining the exact aetiology of AP may be challenging in some cases. For example, alcohol is not only 
known as an independent risk factor for AP but can also increase serum TG concentrations, as mentioned before. 
In addition, mild-to-moderate elevation in TG concentrations can be observed in the early phase of AP, regard-
less of  aetiology167. Since TG concentrations can rapidly decrease during fasting state after the diagnosis of AP, 
the measurement of TG concentrations on (or shortly after) admission is crucial.
The number of events, which refer to positive outcomes in certain aetiologies were relatively high in case of 
severity (1516 severe events occurred out of 2556 HTG-AP patients in Fig. 2a) and partly in mortality (10,161 
events/620,027 BAP patients in Supplementary Figure S13a) and recurrence rate outcomes (1671 events/5254 
AAP patients in Supplementary Figure S10a). Smaller number of events (9–97) could be included in the analysis 
of other outcomes (Table 1). Low event rates can have detrimental influence on the reliability of the  results168,169. 
Based on the studies mentioned above, the results of all severity comparisons, mortality and recurrence rates in 
comparisons of AAP vs. BAP are strongly reliable. Most of the other calculations have lower reliability but there 
is no precedent to contradict the results of severity.
The current meta-analysis has strengths and limitations that should be noted. The major strengths are the 
following: we included a large number of articles. Four major aetiologies were analysed, leaving out miscellane-
ous or idiopathic backgrounds. For the analysis of severity, we only included articles where severity was defined 
according to the RAC, which provided a clear and consistent base for the comparisons. In addition, we compared 
mild to moderately severe and severe (“non-mild”) AP groups, which further refined our analysis. The quality 
of the involved articles determines the value of pooled data. There has been high variability in methodology of 
the studies which may have unintended effects on the final results and interpretation, study populations were 
diverse in age and gender, which might cause heterogeneity in aetiologic distribution. Aetiologies were not 
necessarily defined the same way. Certain outcomes (e.g. necrosis) were only evaluated by a limited number of 
studies, especially in case of HTG-AP, which may be the reason that no statistically significant difference could 
be detected between HTG-AP and other aetiologies or no statistical analysis could be performed. One article 
analysed data from 1975 to 2010, which was only applied for the assessment of recurrence rate. Another article 
contributed 1,165,777 patients to the analysis, which was only used for the evaluation of mortality. In addition, 
only articles published in English or Hungarian were included.
Conclusions
AP is a complex disorder mediated by metabolic, environmental and genetic factors, which can lead to death in 
the most severe forms. Therefore, clinicians should be more alert for a severe disease course in the at-risk patients. 
Our observations highlight the importance of disease aetiology. We found association between aetiology and the 
development and course of AP. HTG proved to carry the highest risk for non-mild (moderately severe and severe) 
AP, which was followed by AAP; the least severe disease forms were observed in BAP and PAP. It is essential to 
determine the cause of the disease in time to apply the most appropriate therapy. Based on the results, greater 
emphasis should be placed on determining aetiology on admission, especially in case of HTG-AP.
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